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Abstract
Background Recent meta-analysis has demonstrated no
significant differences in diagnostic accuracy among differ-
ent imaging techniques (US, MRI and CT) in the evaluation
of Crohn’s disease (CD). High-resolution bowel ultrasound
has emerged as an alternative imaging technique for the
diagnosis and follow-up of patients with CD, being as
accurate as CT and MR for detecting intramural and
extramural extension of the disease. B-Mode US can
evaluate the localization and length of the affected intestinal
segments and allow identification of transmural complica-
tions, stenosis and intestinal obstruction. Doppler techni-
ques are tools that visualize and quantify bowel
vascularization. Contrast-enhanced ultrasound (CEUS) is a
new technique that involves IV administration of an
ultrasound contrast agent with real-time examination,
providing an accurate depiction of the bowel wall micro-
vascularization and the perienteric tissues. The introduction
of imaging quantification techniques enables an objective
quantitative measurement of the enhancement.
Method and results The article reviews the technique,
sonographic findings, advantages and limitations, and
clinical applications of contrast-enhanced US in the
evaluation of Cohn’s disease. Current CEUS applications
in CD are: CD activity assessment, evaluation of inflam-
matory masses, distinguishing phlegmons from abscesses,
characterization of stenosis by differentiating fibrosis from
inflammation, monitoring the efficacy of drug treatments
and improving the detection of disease recurrence.
Conclusion CEUS is an emerging technique that is part of
the entire sonographic evaluation, with a role in the
diagnosis and follow-up of CD, thus improving therapy
planning and monitoring of the efficacy of treatment.
Keywords Crohn’s disease.Ultrasound.
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Inflammatory bowel disease
Introduction
Crohn’s disease (CD) is a chronic transmural intestinal
inflammatory disease that primarily affects young individ-
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with periods of relative quiescence.
Cross-sectional imaging techniques have been proposed
as effective diagnostic techniques to assess the mural and
perivisceral changes in CD [1]. A recent meta-analysis has
demonstrated no significant differences in diagnostic
accuracy among ultrasound (US), MRI and CT in the
evaluation of CD [2]. Because of the relapsing nature of the
disease and its prevalence in young individuals, frequent re-
evaluation is necessary over the years in many patients, and
techniques without ionising radiation should be considered
in this population. As far as we know, there are four studies
comparing B-mode US and MRI in the same group of
patients [3]. In three of them, US performed better than
MRI, although significant differences were not found. In
our opinion the choice of imaging technique depends on
local availability and the skill of the radiologist. Advan-
tages of US over MRI include the lower cost, higher patient
acceptance and shorter scan time.
US has advantages over CT, as it is free of ionising
radiation,non-invasive,well-toleratedandeasilyrepeatablein
patient clinical follow-ups. In recent years, high-resolution
bowel ultrasound has emerged as an alternative imaging
technique in the diagnosis and follow-up of patients with CD,
being as accurate as CT or MRI for detecting intramural and
extramural extensions of the disease [4, 5].
Contrast-enhanced ultrasound (CEUS) is a new tech-
nique that provides accurate depiction of bowel wall
perfusion and the perienteric tissues after IV administration
of microbubble contrast agents with real-time examination.
In this article, we describe the CEUS technique in the
evaluation of patients with CD, illustrate the sonographic
findings and depict clinical CEUS applications, including
the assessment of disease activity, evaluation of complica-
tions, characterisation of stenosis, monitoring the efficacy
of drug treatments or detection of disease recurrence.
Description of the sonographic image and technique
The normal bowel wall has a layered appearance, often
referred to as mural echo-stratification (Fig. 1). Stratifi-
cation appears as five concentric alternating hyperechoic
and hypoechoic layers, where the hyperechoic central
layer corresponds to the submucosa and the hypoechoic
external layer to the muscularis propria. These layers
become more prominent in CD because of transmural
inflammation and oedema. The main ultrasonographic
sign in CD consists of wall thickening >3 mm [6].
Moreover, segments of diseased bowel often appear rigid
with loss of normal peristalsis.
A general survey of the abdomen with gradual and
gentle compression techniques should be performed with a
3–5-MHz convex array transducer, but in most of the cases
high-resolution convex or linear probes (>5 MHz) are
indispensable for detailed examination of the bowel wall
and the surrounding mesentery.
B-Mode US can evaluate the localisation and length of
the affected intestinal segments and identifies complica-
tions such as fistulae, abscesses, stenosis and intestinal
obstructions [4, 5].
Transmural extension of the disease occurs in 20–40% of
patients at some time during the course of the disease [7].
Intramural deep ulcers or fissures that contain gas can be
Fig. 1 a B-mode US shows the longitudinal section of a thickened
intestinal wall (arrows) in a patient with CD. The stratification as five
concentric layers is clearly identified with a high-resolution convex
probe. Fluid-filled lumen appears black (*). b Transverse section of
two adjacent intestinal segments in a different CD patient: US
appearance of the wall of a normal ileal segment (arrows, A) is
similar to the adjacent bowel (B) showing a significant wall
thickening. Fluid-filled lumen (L)
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initially are located in the thickened wall, but when
they extend into the serosa may become extramural.
Fissures or fistulae appear as tubular hypoechoic tracts,
the former in the mesentery adjacent to the inflamed
loops (Fig. 2), and the latter between intestinal loops
(enteroenteric fistula) (Fig. 3) or between loops and other
internal structures such as the bladder or the skin. In
some cases, if there are bubbles of extraluminal gas in the
tracts, it is possible to see them as hyperechoic foci.
Hypoechoic tracts may have a blind end in the mesentery
or be internal to an inflammatory extraintestinal mass,
either a phlegmon (hypoechoic mass with irregular
poorly defined borders) or an abscess (complex collec-
tion frequently with echogenic bubbles of gas and a well-
defined wall).
A thickened, rigid bowel wall is identified at the site
of stenosis with dilatation of the proximal bowel
(>3.0 cm). These lesions are often associated with
increased proximal peristalsis and retropulsion of bowel
contents.
Contrast-enhanced ultrasound
Basic principles of US contrast agents
US contrast agents are exogenous substances that can be
administered in the blood pool to enhance the ultrasound
signals. All the agents contain gas-filled microbubbles with
a diameter of 2–6 μm, which are surrounded by a shell
composed of varying lipids or polymers. The gas and the
shell influence the half-lives of the microbubbles and their
response to insonation.
There are two kinds of US contrasts agents for intestinal
imaging:
Air-filled agents, named first-generation contrast agents
(for example, SHU508, Levovist®), can be used with high
mechanical index intermittent. The microbubbles can be
disrupted, releasing a strong, but transient irregular har-
monic signal that increases the Doppler signal intensity on
colour Doppler sonography. Indeed, such contrast agents
are not true contrast agents but rather vascular Doppler
signal enhancers. Rupture of the microbubbles due to high
pressure is a significant limitation for real-time imaging, so
currently these contrast agents are not used in clinical
practice.
Second-generation US contrast agents (for example, BR-
1, Sonovue®) are filled with gases other than air. These new
US contrast agents oscillate without destruction at low
mechanical index, producing harmonic frequencies that are
multiples of the transmitted frequency (non-linear funda-
mental echoes), allowing real-time imaging of microbubble
Fig. 2 A 42-year-old man with CD and extramural disease. a
Longitudinal US scan depicts a blind-end hypoechoic tract (arrows)
originating from the thickened intestinal wall that represents a fistula,
penetrating the mesentery (*). The stratified appearance of the bowel
is lost focally at the site of the penetrating ulcer. b Macroscopic view
of a transverse section of the surgical specimen through a fistulous
tract (arrows) in the mesentery (*). Note the hyperaemic and thickened
serosa of the resected intestinal segment
Fig. 3 Enteroenteric fistula. US appearance of an enteroenteric fistula
seen as a hypoechoic tract with internal echoes (air bubbles) (arrow),
connecting the caecum (c) and a thickened ileal loop (I)
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specific software in the ultrasound equipment enables the
visualisation of the microbubble signals without the
fundamental grey-scale echoes. Second-generation contrast
agents with low-power insonation techniques are routinely
used in clinical practices.
Fig. 5 Acute exacerbation of CD in a 43-year-old man. a A thickened
ileal wall is identified in basal US (arrows). b CEUS and (c) the
corresponding MR image (post-contrast coronal VIBE section) show a
layered enhancement in the involved segment (arrows)
Fig. 4 a Longitudinal B-mode US scan of the intestinal involved
segment with a multilayered appearance. Hyperechoic submucosa (S).
b Longitudinal US scan in the contrast-specific mode before contrast
agent administration, with the signal almost completely suppressed by
the software. Note that the submucosa (S) can be seen. c Diffuse
transmural contrast enhancement is seen after specific contrast agent
injection. Arrows point to the anterior and posterior thickened
intestinal wall
642 Insights Imaging (2011) 2:639–652CEUS technique in the evaluation of patients
with Crohn’s disease
The procedure is performed in two steps. An accurate
baseline US and colour Doppler exploration is always
performed prior to the contrast-enhanced study. Only after
the initial grey-scale examination has detected the location
and extension of inflammatory bowel disease can we
proceed to evaluate the area of interest with CEUS.
We choose the thickest bowel segment or segments to
perform the quantitative analysis of the contrast agent
enhancement. We employ a 3–6-MHz convex transducer to
perform the bowel study with CEUS. A low mechanical
index (MI<0.10) and wideband harmonic mode (Pulse
inversion, Toshiba, Tokyo, Japan) are used.
We employ the sulfur-hexafluoride based second-generation
echo-signal enhancer (SonoVue®, Bracco, Milan, Italy) injected
as a bolus in units of 1.2 ml through a three-way 20-gauge
catheter in a forearm vein, followed by 10 ml of a normal saline
solution (0.9% NaCl). A different range of 1.2-ml boluses of
contrast agent can be used for each patient, depending on the
number of involved bowel segments. In our experience, with a
3–6-MHz convex transducer, the use of higher doses of contrast
agents does not improve the image or change the quantitative
measurement. However, when using higher frequency trans-
ducers, either convex or linear-array probes, the best results are
obtained with the administration of a 5-ml bolus.
For each examination the recording starts a few seconds
before the intravenous administration of the contrast agent
and continuous imaging is performed for 40 s. A
predetermined region of interest (ROI) is selected and the
software determines the brightness over a defined time
period. The whole examination is stored in the scanner as a
videoclip and subsequently sent to a personal computer for
conversion into an .avi format video file.
Immediately after intravenous administration of the con-
trast agent, the harmonic mode is switched on. The gain
setting has previously been regulated to obtain an anechoic
bowelwall.Thehyperechoicsubmucosallayerandthecentral
hyperechoic line arising from the bowel lumen can be seen in
some cases in the harmonic mode (Fig. 4). The transducer
must be kept as still as possible on the previously selected
image of the intestinal segment. Approximately 12–20 s after
contrast agent injection the bowel wall enhances, achieving
Fig. 6 a Sagittal B-mode US scan identifies mild circumferential wall thickening in two ileal loops (arrow). b CEUS and (c) the corresponding
MDCT demonstrates contrast agent enhancement of the intestinal wall
Insights Imaging (2011) 2:639–652 643the maximum enhancement in approximately 5 s [video 1,
Supplemental Material]. Afterwards the enhancement
decreases gradually. No contrast agent pooling is observed
in the intestinal wall because microbuble contrast agents
present a pure intravascular distribution.
Contrast-enhanced ultrasound of intestinal wall
hyperaemia
Both colour and power Doppler sonography have been used
to assess the wall hypervascularisation of inflamed loops.
However, their resolution for small vessels is limited, and
changes in wall vascularity detectable by these techniques
are very likely only due to large arteries feeding the
vascular bed. With the advent of low-mechanical-index
real-time harmonic sonography associated with second-
generation contrast agents, which remain for a longer
period in the intestinal wall microcirculation, it is now
possible to provide an accurate mapping of the intraparietal
vasculature, even identifying low-velocity flows in small
vessels.
Histological studies have demonstrated that neovascular-
isation of the bowel wall, characterised by the development
of new capillary vessels in the lamina propria and
submucosa, is an early pathological change occurring in
patients with active CD [8]. The activation of the
angiogenesis is the basis for visualisation of inflamed
bowel walls by imaging methods employing intravenous
contrast agents. CT enterography and MRI with oral
contrast agents are sensitive markers of small bowel
inflammation and correlate with histological findings of
inflammatory CD [9, 10]. Prior studies have shown a high
correlation between signal enhancement at CEUS and MRI,
confirming that both techniques are capable of objective
evaluation of the increase in vascularisation of the bowel
wall (Figs. 5 and 6)[ 11].
CEUS can identify different patterns of enhancement of
the thickened bowel wall. Pattern 1 corresponds to a
complete enhancement of the bowel wall (Fig. 7); pattern
2 corresponds to enhancement of the inner layers (except
the muscularis propria) (Fig. 8); pattern 3 depicts enhance-
Fig. 8 Diffuse transmural enhancement. a B-mode US shows a
hypoechoic thickened wall (arrows). b CEUS shows complete and
homogeneous enhancement of the entire wall, from the mucosa to the
serosa layers
Fig. 7 Inner layer enhancement. a B-mode US shows a thickened
and layered bowel loop. Anterior wall is between marks. b CEUS
depicts intense enhancement of the inner and intermediate layer, with
absence of enhancement in the muscularis propria (hypoechoic
external layer) (*)
644 Insights Imaging (2011) 2:639–652ment only of the intermediate layer (submucosa); pattern 4
corresponds to the complete absence of enhancement.
Quantitative measurement of bowel wall vascularity
To assess the vascularisation of the involved bowel
loop, the contrast agent uptake over a period of 40 s is
measured by quantitative analysis of the brightness in
regions of interest (ROI) localised in the brighter zone
of the intestinal wall, using a dedicated software
installed into the US equipment or by a specific
software of quantification installed on a personal
computer. The software automatically obtains a
brightness-time curve (Fig. 9). The manually defined
area of the ROI is variable on each patient depending on
the thickness of the wall, but has to be at least 2 cm
2.T h i s
provides objective assessment of the signal quantity,
which can be considered an expression of parietal vascular
density. The vascularity of the intestinal segment is
measured in grey-scale levels from 0 (black pixels) to
255 (white pixels) by the dedicated software.
We assess the quantitative measurement of contrast agent
enhancement as the difference between the baseline
brightness before contrast agent injection and the value of
maximum enhancement. This is considered as the absolute
change of vascularity during the examined period and is
interpreted to represent the vascularity of the small bowel
wall. We also calculate the percentage of increase in wall
brightness by using the following formula: [(brightness post-
contrast –brightness precontrast) × 100]/brightness precontrast.
Other softwares allow the calculation of several different
parameters, including the slope of the first ascending tract
of the curve, time-to-peak enhancement and area under the
enhancement curve.
Fig. 10 a Transversal US scan of a thickened terminal ileum wall
(arrows). b Post-contrast agent image shows scarce enhancement of
the internal layers. A 27% increase in wall brightness was measured in
the brightness-time curve (ROI in bowel wall). Mild endoscopic
disease was demonstrated in the ileocolonoscopy
Fig. 9 a Transverse B-mode US scan of the intestinal involved
segment shows a deep ulcer with echogenic gas (arrow). The
thickened anterior wall is between marks. b CEUS: Transverse US
scan in the contrast-specific mode. Measurement of bowel wall
vascularity, after second-generation contrast agent injection, in a
manually defined ROI, obtaining the brightness-time curves over a
period of 40 s. In this case, the absolute and percentage of
enhancement increases were 71 and 122, respectively (baseline value
58, maximum value 129)
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sonography: curves of brightness-time analysis are theoret-
ically more reliable than semiquantitative measurements of
the number of vessels. Motion artefacts produced by
peristalsis or intestinal contents do not impair CEUS as
happens with colour Doppler (video 2, Supplemental
Material). Even if the ROI cannot be continuously placed
over a defined area because of motion of the intestinal wall,
it is possible to analyse the contrast agent enhancement
from individual images.
Fig. 11 Perienteric phlegmon. a Panoramic US view shows a
hypoechoic inflammatory mass (asterisk) between the ascending colon
(c) and a thickened intestinal loop (I). b Colour Doppler depicts
increased Doppler signal in the intestinal wall and absence of
vascularisation in the inflammatory perienteric mass. c Post-contrast
image obtained after contrast agent injection detects intense enhance-
ment of the lesion identifying the mass as a perienteric phlegmon
Fig. 12 Anterior abdominal wall abscess. a B-mode US shows a
thickened terminal ileum (TI) and two possible collections, in the
anterior abdominal wall (arrows) and intraperitoneal (*). b Hypo-
echoic collections depict peripheral flow on colour Doppler. c Post-
contrast agent image shows high enhancement of the intraperitoneal
collection corresponding to a phlegmon (*). The collection located in
the anterior abdominal wall is an area completely devoid of micro-
bubble signal, representing an avascular abscess (arrows). CEUS
defines its size better
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possible, even with the newer machine, to evaluate the
enhancement if the bowel wall is not clearly identified or if
it is too thin; also each intestinal segment evaluated needs
an injection of contrast agents. Furthermore, CEUS needs
specific software to quantify the enhancement, and it is time
consuming.
Clinical applications of CEUS in CD
CD activity assessment
Crohn’s disease is a chronic inflammatory disease charac-
terised by episodes of inflammation alternating with periods
of remission. Therefore, it requires periodic assessment of
the inflammatory activity to plan proper treatment [12].
Many disease-specific instruments to measure inflammatory
activity have been evaluated, but to date no diagnostic
technique is regarded as the standard reference for a reliable
and reproducible quantification of CD inflammatory activity.
In the routine clinical practice of gastroenterologists, this
evaluation is currently based on the integration of clinical
symptoms, physical findings, laboratory parameters, endoscopy
and imaging tests [13].
In previous studies, both bowel wall thickness deter-
mined by sonography and vascularity within the diseased
bowel wall assessed by colour Doppler have been signif-
icantly related to clinical activity indexes [14]a n d
endoscopic activity [15, 16] in CD.
Wall enhancement after iv administration of Sonovue®
has been studied as a parameter reflecting bowel inflam-
mation. The reason for this phenomenon is assumed to be
an increase of blood flow and local tissue perfusion
(because of vasodilatation and neovascularisation). Mural
hyperenhancement in CEUS correlates with active disease.
To reliably quantify this finding, either a subjective
categorical scale or an enhancement quantification can be
used:
Semiquantitative evaluation: Serra et al. [17], who
considered as active only the patients with abundant bowel
wall enhancement (including both complete enhancement
of the bowel wall or enhancement of the inner layers),
reported a sensitivity and specificity of 81% and 63%,
respectively, in distinguishing active and inactive disease
according to the CDAI index (Figs. 7 and 8). Migaleddu et
al. [18], using the same criteria as Serra et al., had a
sensitivity and specificity of 93.5% and 93.7%, respectively,
in distinguishing active and inactive disease according to
endoscopy/biopsy as the reference standard.
Quantitative measures of bowel enhancement by quan-
titative analysis of brightness: the contrast agent enhance-
ment of the bowel wall in patients with active endoscopic
disease is significantly increased in comparison with the
normal endoscopic bowel wall (Figs. 9 and 10). In the
study of Ripollés et al. [19] a threshold brightness value of
45% increment had an overall sensitivity of 95% and
specificity of 78% in predicting moderate or severe
endoscopic inflammation.
CEUS studies assessing inflammatory activity are based
solely on ileocolonoscopy, so evidence of their ability is
proved only for the colon and terminal ileum, while CD can
also be localised in the small bowel.
Mural thickening correlates with inflammatory activity
demonstrated by endoscopy. However, similar to the results
of some previous CT or MR imaging studies [9, 20], CEUS
has showed that inflammatory activity has the best
correlation with mural enhancement after contrast agent
injection rather than with the assessed bowel wall thickness
[19].
Fig. 13 A 63-year-old man with CD and a predominant fibrotic
stenosis. a US scan demonstrates stenosis of the lumen (arrows) with
severe dilatation of the proximal bowel (asterisk). b Post-contrast
agent image shows mild enhancement of the bowel wall.
Corresponding brightness-time curve shows a 50% increase of
enhancement. Pathological examination of the surgical specimen
showed significant fibrostenosis with scarce-grade of inflammation
Insights Imaging (2011) 2:639–652 647Fig. 15 A 37-year-old man with recurrent CD and obstructive signs. a
Longitudinal US scan demonstrates marked thickening of the neo-
terminal ileum (arrows) with dilated proximal loop. b CEUS at 20 s
after injection shows intense enhancement of the inner layers of the
wall, with absence of contrast in the muscularis propria (m). It is
associated with an increased number of adjacent mesenteric vessels
(comb sign) (arrows), a finding described in CT and MRI studies
as suggestive of active lesions. c Correlative image of MDCTshows
the thickened enhancing wall of the stenotic segment with a
stratified appearance (target sign) (arrows). Pathological analysis of
the surgical specimen showed coexistence of inflammatory and
fibrous components
Fig. 14 A 25-year-old man with CD and obstructive symptoms. a
Axial sonographic scan shows long luminal stenosis of the ileum
(arrows) associated with prestenotic dilation (asterisks). b Post-
contrast image obtained 20 s after contrast agent injection depicts
enhancement of the proximal segment of the stenosis (large arrow) as
well as of the proximal dilated intestinal loops, whereas there is scarce
enhancement in the midportion of the stenosis (shorts arrows). c
Surgical specimen shows a short segment of fibrous stenosis (short
arrows) and severe inflammation of the proximal segment (large
arrow)
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character. Quantitative measures of bowel enhancement by
quantitative analysis of brightness are more objective and,
above all, more precise. However, the selection of the ROI
to measure the contrast agent enhancement depends on the
radiologist, potentially introducing an interobserver vari-
ability. The exact threshold value for defining abnormal
mural enhancement will vary depending of the method of
measurement. However, studies comparing quantitative
measures obtained with the software packages of the
different kinds of commercially available ultrasound equip-
ment have not been performed.
Characterisation of inflammatory masses
Extraintestinal complications in CD include phlegmon and
abscess formation. The differentiation between these two
entities has important implications for patient management,
because abscesses can require surgical or percutaneous
drainage. Moreover, with new therapies, especially biological
therapy (antibodies to tumor necrosis factor alpha drugs, anti-
TNF), the presence of abscesses should be ruled out before
starting the treatment, because undetected abscesses may
become clinically apparent (with risk of sepsis) only after the
closure of the drainage from a fistulous tract.
On US and colour Doppler examination a phlegmon
appears as a hypoechoic mass with no identifiable wall
and internal colour signals. On the other hand,
abscesses are present as hypoechoic fluid collections
with an irregular wall and peripheral flow on colour
Doppler. However, sometimes it is difficult to distin-
guish inflammatory infiltrates from abscesses if gas,
fluid or clear signals of colour Doppler in their interior
are missing.
CEUS is extremely useful in distinguishing these two
entities since phlegmons show intra-lesional enhancement,
while abscesses show enhancement only in the wall
(Figs. 11 and 12)[ 21].
Stenosis evaluation
Stenosis occurs in 12–54% of CD patients [22]. It is
associated with significant morbidity and impaired quality
of life. Treatment options are based on the differentiation
between inflammatory versus fibrous-predominant stric-
tures. The former can potentially be managed with
conservative medical treatment, and the latter necessitates
endoscopic balloon dilation or surgery. Colonoscopy is
currently considered the standard method for assessing
stenosis, but this technique can only provide information of
Fig. 16 A 24-year-old
woman with CD. a CEUS
before treatment with the
anti-TNF drug shows marked
enhancement in the involved
loop (the absolute and
percentage of enhancement
increases were 96 and 168,
respectively). b CEUS
examination depicts a reduction
of the enhancement (percentage
increase of 59%) in the same
loop following the induction
treatment with anti-TNF
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stenosis located in the small bowel.
The combination of power Doppler sonography with
the use of a first-generation contrast agent (Levovist®)
appears to be effective in differentiating between hyper-
vascularised inflammatory stenosis and hypovascularised,
predominantly cicatritial stenosis [23].
Similarto CTor MRI, inflammatory stenosisshows abundant
bowel wall enhancement after contrast agent injection (including
both complete enhancement of the bowel wall or enhancement
of the inner layers) that can be measured by quantitative analyses
of brightness in predefined ROIs (Fig. 13)[ 24, 25]. A study
presented only in abstract form reported that the percentage of
increase in contrast agent enhancement of the bowel wall in
patients with inflammatory strictures is significantly greater in
comparison with patients with fibrotic strictures using surgical
pathological examination as the reference standard, 82±17%
versus 63±28%, respectively [24].
CEUS may help to differentiate between inflammato-
ry and fibrostenotic lesions. However, in many cases a
mixture of acute inflammation and fibrosis in the same
stenotic segment can be found in the pathological
analysis, making impossible the diagnosis (Fig. 14)
[26], or even in some cases a stenotic segment can have
some zones of inflammation and different zones with
fibrosis as the predominant component, making the
differentiation difficult (Fig. 15). Thus, although future
prospective studies are needed, CEUS may have a role in
differentiating hypervascular strictures from hypovascular
fibrotic strictures.
Fig. 18 A 43-year-old woman with previous ileocolic resection for
CD, with recurrence at the anastomotic site. a Longitudinal US scan
shows mild thickening (3.2 mm) of a short segment of the anastomosis
(arrows). b CEUS after specific contrast agent injection depicts
intense enhancement (100%) of the anastomosis allowing the
diagnosis of recurrent disease. Ileocolonoscopy showed a Rutgeerts
score of 3
Fig. 17 Crohn’s disease in a 20-year-old woman in clinical remission
after effective medical treatment. Scheduled sonographic exam: a
transverse sonographic scan of the caecum shows thickening of the
wall with preserved stratification. b Measurement of bowel wall
vascularity after second generation contrast agent injection in a
manually defined ROI localised in the ileal wall. The percentage of
enhancement increase in wall brightness was 100%. The patient did
not change the treatment and 6 months later required hospitalisation
due to an enterocutaneous fistula (see Fig. 12). There is a correlation
between residual enhancement after treatment and an unfavourable
outcome
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For an optimal evaluation of the efficiency of treatment, the
patient must be monitored frequently; therefore, an appro-
priate monitoring technique should be noninvasive, without
ionising radiation and, above all, patient-friendly. US fulfils
all these requisites, therefore it can be performed repeatedly.
Bowel wall thickness and colour Doppler in the wall
have been used to evaluate the response to classical medical
treatments [27–29].
Quantitative techniques for assessment of bowel wall
vascularisation by CEUS can determine changes of contrast
agent enhancement, reflecting the response of intestinal
inflammatory disease to therapy at follow-up (Fig. 16). It
has been published that quantitative parameters by CEUS,
for example the slope of the first ascending tract or the
curve or the area under the enhancement curve, decrease
significantly after effective pharmacological treatment [30].
Potential differences in the results obtained with different
software are not important in monitoring the treatment,
because patients can be evaluated by the same radiologist
with the same machine.
However, despite the initial clinical improvement after
treatment, many patients relapse on discontinuing treatment
once maintained remission of the disease has been
achieved. Residual hyperaemia in the affected bowel wall
by colour Doppler may detect patients with incomplete
histopathological remission, reflecting subclinical inflam-
mation, with a predisposition to relapse [28].
Patients with quiescent CD after medical treatment with
a thickened enhancing wall after contrast agent injection
also present a higher risk of relapse, with a higher number
of hospitalisations and surgeries (Fig. 17)[ 31]. This fact
could have treatment implications; patients in clinical
remission with persistent enhancement should be monitored
closely or undergo prolonged treatment, whereas in the
absence of or scarce enhancement, therapy could be stopped.
Moreover, after the introduction of new therapies,
especially biological therapy, endoscopic mucosal healing
has been proposed to be the treatment goal, because
mucosal healing is associated with a decrease in rates of
hospitalisation and surgery. Endoscopic examination is
invasive and unpleasant, with poor patient compliance, so
it cannot be performed repeatedly. Furthermore, it cannot be
used to assess proximal segments of the small bowel.
Future prospective studies comparing CEUS with colo-
noscopy are required to determine if sonographic enhance-
ment changes correlate with endoscopic changes.
Postoperative follow-up and detection of disease recurrence
Two studies have demonstrated that US can identify the
recurrenceofCD withasensitivityof81–82%whencompared
withendoscopy[32, 33]. In both of these studies a bowel wall
thickness greater than 5 mm was considered pathological.
The detection of an increased enhancement by CEUS in
intestinal segments with mild mural thickening (<5 mm) may
improve the diagnosis of disease recurrence (Fig. 18)[ 34].
Conclusions
US today has clearly defined roles in the diagnosis and
follow-up of CD, thus improving therapy planning and
monitoring the efficacy of treatment. CEUS is an emerging
technique that must be considered part of the entire
sonographic evaluation. It has good diagnostic accuracy,
with results comparable with those of other imaging
techniques, such as CT or MR. CEUS of the intestinal tract
does not require any specific preparation, so it is well-
tolerated and accepted by patients and therefore can be
performed repeatedly, a fact that represents the main
advantage of this technique over other cross-sectional
imaging procedures. CEUS is especially useful to evaluate
the inflammatory activity of CD and to monitor the
efficiency of treatments.
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